Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events
Authors: Prakriti Gaba, Deepak L. Bhatt, Gilles R. Dagenais, Jackie Bosch, Aldo P. Maggioni, Petr Widimsky, Darryl Leong, Keith A. A. Fox, Salim Yusuf, John W. Eikelboom, Salim Yusuf, Keith AA Fox, John W Eikelboom, Jackie Bosch, Victor Aboyans, Marco Alings, Sonia S Anand, Alvaro Avezum, Deepak L. Bhatt, Kelley RH Branch, Patrick J Commerford, Nancy Cook-Bruns, Gilles R Dagenais, Antonio L Dans, Rafael Diaz, Georg Ertl, Camilo Felix, Tomek J Guzik, Robert G Hart, Masatsugu Hori, Ajay K Kakkar, Katalin Keltai, Matyas Keltai, Jae-Hyung Kim, Andre Lamy, Fernando Lanas, Basil S Lewis, Yan Liang, Lisheng Liu, Eva M Lonn, Patricio Lopez-Jaramillo, Aldo P Maggioni, Kaj P Metsarinne, Paul Moayyedi, Martin O'Donnell, Alexander N Parkhomenko, Leopoldo S Piegas, Nana Pogosova, Jeffrey Probstfield, Lars Ryden, Mukul Sharma, P Gabriel Steg, Stefan Stoerk, Andrew M Tonkin, Christian Torp-Pedersen, John Varigos, Peter B Verhamme, Dragos Vinereanu, Petr Widimsky, Khalid Yusoff, Jun Zhu
Journal: JAMA Network Open (2022)

Importance In the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial, there was a significant reduction in the adjudicated primary outcome among patients with stable atherosclerotic vascular disease randomized to dual pathway inhibition (rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily) vs aspirin monotherapy, but not with rivaroxaban 5 mg twice daily vs aspirin monotherapy. Whether the results are similar without adjudication is unknown. Objective To examine the impact of dual pathway inhibition (with rivaroxaban plus aspirin) or rivaroxaban monotherapy compared with aspirin monotherapy on investigator-reported CV events and to understand the extent of concordance between investigator-reported and centrally adjudicated clinical events. Design, Setting, and Participants This is a secondary analysis of the COMPASS trial, an international, double-blind, double-dummy, randomized clinical trial with a 3-by-2 partial factorial design that evaluated participants with stable atherosclerotic vascular disease receiving rivaroxaban plus aspirin, rivaroxaban monotherapy, or aspirin monotherapy. End points were collected by blinded site investigators and adjudicated by a blinded clinical end point committee. Data were analyzed from March 2013 through February 2017. Interventions Participants received dual inhibition pathway (2.5 mg rivaroxaban twice daily plus 100 mg aspirin once daily), rivaroxaban monotherapy (5 mg twice daily), or aspirin monotherapy (100 mg once daily). Main Outcomes and Measures The primary efficacy outcome was a composite of cardiovascular (CV) death, stroke, or myocardial infarction (MI). Adjudicated and investigator-reported end points were compared. Results A total of 27 395 patients (mean [SD] age, 68.2 [7.9] years; 78.0% men) were assessed, including 9152 patients randomized to dual pathway inhibition, 9117 patients randomized to rivaroxaban monotherapy, and 9126 patients randomized to aspirin monotherapy. Adjudication reduced the number of events by 10% to 15% for most end points. Among investigator-reported end points, dual pathway inhibition significantly reduced the rate of the primary efficacy outcome compared with aspirin alone (411 patients [4.5%] vs 542 patients [5.9%]; hazard ratio [HR], 0.75 [95% CI, 0.66-0.85]; P &amp;amp;lt; .001), with similar reduction in adjudicated end points, (379 patients [4.1%] vs 496 patients [5.4%]; HR, 0.76 [95% CI, 0.66-0.86]; P &amp;amp;lt; .001). Likewise, effects on ischemic end points were highly concordant (κ statistic = 0.94 [95% CI, 0.93-0.95] for the primary composite end point). Unlike with adjudicated outcomes, there was a significant reduction in the primary end point with rivaroxaban monotherapy vs aspirin monotherapy using investigator-reported events (477 patients [5.2%] vs 542 patients [5.9%]; HR, 0.88 [95% CI, 0.78-0.99]; P = .04) compared with adjudicated events (448 patients [4.9%] vs 496 patients [5.4%]; HR, 0.90 [95% CI, 0.79-1.03]; P = .12). Conclusions and Relevance This secondary analysis of the COMPASS trial found that whether assessed by blinded site investigators or adjudicators, dual pathway inhibition significantly reduced CV events among patients with stable atherosclerotic disease compared with aspirin plus placebo. These findings suggest that using investigator-reported events in blinded clinical trials may be a more efficient alternative to adjudication. Trial Registration ClinicalTrials.gov Identifier: NCT01776424